Tonix Pharmaceuticals Holding Corp builds a new R&D centre for developing vaccines and protein-based therapeutics. The new facility will be located in Massachusetts.
The new R&D centre constructed with an area of 40,000 square foot facility will be used as laboratories to provide R&D functions associated with expanding a portfolio of immunology candidates, including vaccines for COVID-19 and biological products for other disorders.
This expansion is made to strengthen the capabilities in process and analytical development. Since US region, seen to be one of the most quickly emerging infectious diseases prone country, needs more domestic onshore capacity to produce vaccines and hence the new R&D facility will support in making vaccines and biologics products suitable for clinical studies by utilising the growing range of vaccine technologies and protein-based therapeutic platforms.
The R&D facility is anticipated to complete its construction and start its operations in 2022.
|Name||Tonix Pharmaceuticals Holding Corp.|
|Type||New R & D Center Constrcution|